Its official ALTH to be taken over !!!!

May 3rd Bithches.......I wrote this may 3rd. 2.44 per share? The worst merger in bio-onc history. I bet berns earns MORE money with AMAG than he does with US? Un fucking real. 2.44 or bankruptcy. What a joke.

 

Allos is dead. AMAG will soon follow as long as Berns has a hand in the direction of the company. Rumor has it that Jim V Caruso is consulting with AMAG....

 

Which is why we are being sold for $2.00 per share. Jim and Paul have the midas touch. I cant wait to start selling Folotyn in the dialysis clinics....

 

From THE STREET today:

Amag-Allos: Worst Bio-Merger in History
Adam Feuerstein
07/20/11 - 08:42 AM EDT

Updated with more deal information.

LEXINGTON, Mass. (TheStreet) -- Amag Pharmaceuticals(AMAG) is merging with Allos Therapeutics(ALTH) in what might be the nuttiest, most nonsensical business combination in biotech history.

The only thing Amag and Allos have in common is that they've largely failed initial efforts to sell their respective drugs, neither of which have anything to do with each other.

Amag's commercial launch of Feraheme, an injectable iron replacement therapy for anemia in patients with chronic kidney disease, has been a major disappointment. The same can be said for Allos' lymphoma cancer drug Folotyn.

Ideally, mergers bring together two companies that can capitalize on their respective strengths to make the sum better, stronger, more capable than the individual parts. Wednesday's merger of Amag and Allos does no such thing. It's just two disparate and under-performing biotech companies getting hitched to, at best, save some money.

"We are very excited about this merger as it creates a combined company with an enhanced commercial presence in attractive market segments supported by a more efficient organizational structure," said Brian Pereira, CEO of Amag in a statement that fails on so many levels to rationalize this deal.

Pereira, by the way, will retain the CEO title in the as-yet-unnamed combined company.

Under terms of the deal, Allos shareholders will receive a fixed ratio of 0.128 shares of Amag common stock for each share of Allos common stock they own. At Amag's Tuesday closing price of $19.07, the deal values Allos at $2.44 a share, or $260 million total.

Allos shares closed Tuesday at $2.06 a share.

Allos received U.S. approval for Folotyn in September 2009. At that time, Allos shares traded for around $8 a share. That was basically the high point for Allos's stock price.

Amag's Feraheme was approved in the U.S. in July 2009 when Amag shares traded around $56 a share. Like Allos, Amag' stock price never saw brighter days. The stock fell steadily as Feraheme sales lagged expectations.

The merger of Amag and Allos: Not exactly a match made in heaven.

 

Merger will need to consolidate services and people to make sense.

 

Consolidate Berns, Schick, and Smith in addition to the entire home office in colorodo. Garry Allen should be retained to sniff Brian Pereira balls and to act as a stunt double for Dr Lee Allen.

 

Paul Bern's was finally able to sell the company he single handedly destroyed. Just how much will he get; a nice severance salary/healthcare for several yrs and vesting of stock which he has around 1.75MM, which after taxes will net out to around $750.000. Thats chump change to Paul just as him how much he spend on cars... Berns you really fucked this UP, and the sad thing is that YOU will be getting more than anyone due to this merger. Do the right thing and give back all everything to the folks that really need it!! Come on Paul Berns grow some balls and do whats right!!

 

Nope! Pauli is keeping every penny. Paul Retiring in FL when this over. Paul is happy to collect a paycheck for few more months.

 

Sorry we dont sell into dialysis! Yes our fine leadership made the decision to walk away from the biggest market for Feraheme. Why you ask? Our iron is the Mercedes of iron! High priced! Now we sell into oncology without an oncology indication. Our CEO can also pull a rabbit out of a hat. Why the merger? No other company wanted these products. Half of us on either side will be gone. Amag may have upper hand in merger but no one is safe!

 

Still taking credit for shit you had nothing to do with, and no prior knowledge of, aren't you? Still doing this at your new company???

 

Paul Berns posted the original guess on amag. Prior knowledge is not something Paulie admits too.

 

Allos reps will be given more credibility b/c of the hem experience. our salaries won't play a part b/c that's pennies when you don't have to wait 1-2 years to build MD relationships which is what we have.

Have faith.....I like Allos and want to see most of us in the new company.

What's the new name going to be?

 

Almag Biotherapeutic.


Allos reps will not be given credibility because PB and Slick have always blamed us for not meeting the 75 million year 1 target and the fact that we are trending at 41 million this year.